FOUNDATIONONE®LIQUID CDx

PATIENT
Chang, Hua-Wu

TUMOR TYPE
Prostate acinar adenocarcinoma

COUNTRY CODE
TW

REPORT DATE
21 December 2022

ORDERED TEST #
ORD-1523346-01

ABOUT THE TEST FoundationOne®Liquid CDx is a next generation sequencing (NGS) assay that identifies clinically relevant genomic alterations in circulating cell-free DNA.

PATIENT
DISEASE Prostate acinar adenocarcinoma
NAME Chang, Hua-Wu
DATE OF BIRTH 26 September 1958
SEX Male
MEDICAL RECORD # 13896872

PHYSICIAN
ORDERING PHYSICIAN Yeh, Yi-Chen
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN
SPECIMEN ID HWC 09/26/1958
SPECIMEN TYPE Blood
DATE OF COLLECTION 07 December 2022
SPECIMEN RECEIVED 14 December 2022

Biomarker Findings

Blood Tumor Mutational Burden - 1 Muts/Mb
Microsatellite status - MSI-High Not Detected
Tumor Fraction - Elevated Tumor Fraction

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

AR amplification
BCOR S301fs*11
DNMT3A splice site 2174-1G>C
TP53 T125R

Report Highlights

- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 8)
- Variants that may represent **clonal hematopoiesis** and may originate from non-tumor sources: ***DNMT3A* splice site 2174-1G>C** (p. 6)

BIOMARKER FINDINGS	THERAPY AND CLINICAL TRIAL IMPLICATIONS
Blood Tumor Mutational Burden - 1 Muts/Mb	**No therapies or clinical trials. See Biomarker Findings section**
Microsatellite status - MSI-High Not Detected	**MSI-High not detected. No evidence of microsatellite instability in this sample (see Appendix section).**
Tumor Fraction - Elevated Tumor Fraction	**Tumor fraction is considered elevated when ctDNA levels are high enough that aneuploidy can be detected. There is higher sensitivity for identifying genomic alterations and a lower risk of false negative results in specimens with elevated tumor fraction; the positive percent agreement observed between liquid and tissue for defined short variants is ≥ 90% (Li et al., 2021; AACR Abstract 2231) (see Biomarker Findings section).**

GENOMIC FINDINGS	VAF%	THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)
AR - amplification	-	None	None
2 Trials see p. 8			

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS (CH)

Genomic findings below may include nontumor somatic alterations, such as CH. The efficacy of targeting such nontumor somatic alterations is unknown. This content should be interpreted based on clinical context. Refer to appendix for additional information on CH.

DNMT3A - splice site 2174-1G>C ..... p. 6

Electronically signed by J. Keith Killian, M.D. | 21 December 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the therapies listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and/or exhaustive. Neither the therapies nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies. Therapies contained in this report may have been approved by the US FDA or other national authorities; however, they might not have been approved in your respective country. In the appropriate clinical context, germline testing of *APC*, *ATM*, *BAP1*, *BRCA1*, *BRCA2*, *BRIP1*, *CHEK2*, *FH*, *FLCN*, *MEN1*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *NF1*, *NF2*, *PALB2*, *PMS2*, *POLE*, *PTEN*, *RAD51C*, *RAD51D*, *RB1*, *RET*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *SMAD4*, *STK11*, *TGFBR2*, *TP53*, *TSC1*, *TSC2*, *VHL*, and *WT1* is recommended.

Variant Allele Frequency is not applicable for copy number alterations.



HISTORIC PATIENT FINDINGS		ORD-1523346-01 VAF%
Blood Tumor Mutational Burden		1 Muts/Mb
Microsatellite status		MSI-High Not Detected
Tumor Fraction		64%
AR	amplification	Detected
BCOR	● S301fs*11	8.2%
DNMT3A	● splice site 2174-1G>C	0.39%
TP53	● T125R	67.0%

NOTE This comparison table refers only to genes and biomarkers assayed by prior FoundationOne®Liquid CDx or FoundationOne®CDx tests. Up to five previous tests may be shown.

For some genes in FoundationOne Liquid CDx, only select exons are assayed. Therefore, an alteration found by a previous test may not have been confirmed despite overlapping gene lists. Please refer to the Appendix for the complete list of genes and exons assayed. The gene and biomarker list will be updated periodically to reflect new knowledge about cancer biology.

As new scientific information becomes available, alterations that had previously been listed as Variants of Unknown Significance (VUS) may become reportable.

Tissue Tumor Mutational Burden (TMB) and blood TMB (bTMB) are estimated from the number of synonymous and non-synonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of ≥5%, and bTMB is calculated based on variants with an allele frequency of ≥0.5%.

Not Tested = not baited, not reported on test, or test preceded addition of biomarker or gene

Not Detected = baited but not detected on test

Detected = present (VAF% is not applicable)

VAF% = variant allele frequency percentage

Cannot Be Determined = Sample is not of sufficient data quality to confidently determine biomarker status

Electronically signed by J. Keith Killian, M.D. | 21 December 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

BIOMARKER

Blood Tumor Mutational Burden

RESULT
1 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[1-3], anti-PD-1[3-4], anti-PD-1/CTLA4 therapies[5-6] , anti-PD-L1/CTLA4 therapies[7-10]. A Phase 2 multi-solid-tumor trial showed that bTMB ≥16 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD-1 inhibitor alone or in combination with a CTLA-4 inhibitor[5]. In non-small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single-agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb-16 Muts/Mb[1,8-10]. In head and neck squamous cell carcinoma (HNSCC), a Phase 3 trial showed that bTMB ≥16 Muts/Mb (approximate equivalency ≥8 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor[11]. In colorectal cancer (CRC), a Phase 2 study showed that bTMB TMB ≥28 Muts/Mb (approximate equivalency ≥14 Muts/Mb as measured by this assay) was associated with improved OS from a PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor[7].

FREQUENCY & PROGNOSIS

Average bTMB levels in solid tumors other than NSCLC have not been evaluated (PubMed, Mar 2022). The effects of hypermutation on prognosis and clinical features in prostate cancer have not been extensively investigated (PubMed, Feb 2022).

FINDING SUMMARY

Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[12-13] and cigarette smoke in lung cancer[14-15], treatment with temozolomide-based chemotherapy in glioma[16-17], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[18-22], and microsatellite instability (MSI)[18,21-22]. High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents[1-2,4]. Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered.

BIOMARKER

Tumor Fraction

RESULT
Elevated Tumor Fraction

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Specimens with elevated tumor fraction have high circulating-tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management[23-28].

FREQUENCY & PROGNOSIS

Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3)[29]. Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer[30], Ewing sarcoma and osteosarcoma[31], prostate cancer[26], breast cancer[32], leiomyosarcoma[33], esophageal cancer[34], colorectal cancer[35], and gastrointestinal cancer[36].

FINDING SUMMARY

Tumor fraction provides an estimate of the percentage of ctDNA present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single-nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content[37], the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy[38-39].

Electronically signed by J. Keith Killian, M.D. | 21 December 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
AR

ALTERATION
amplification

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Antiandrogens such as apalutamide, bicalutamide, cyproterone, darolutamide, enobosarm, enzalutamide, flutamide, and nilutamide directly target AR, whereas hormone therapies such as the CYP17A1 inhibitor abiraterone and luteinizing hormone-releasing hormone agonists or antagonists modulate androgen production[40-48]. Resistance to androgen deprivation therapy (ADT) commonly occurs in prostate cancer through mechanisms such as increased AR expression, AR activation by tyrosine kinase-dependent signaling, alterations in AR co-activators, expression of alternatively spliced isoforms of AR mRNAs (AR-Vs), and extragonadal synthesis of androgenic compounds[49-53]. Approaches in clinical and preclinical development for prostate cancer include therapies that target AR nuclear translocation and degradation pathways[54-60], single-agent or combinational approaches to suppress androgen biosynthesis[61], and the use of bromodomain and extraterminal (BET) inhibitors that disrupt the interaction between AR and BRD4[62-65]; the latter approach has potential to target AR-Vs[63-64,66]. Limited clinical and preclinical data suggest that selective p300/CBP bromodomain inhibitors such as inobrodib[67] and FT7051[68] are active against AR-activated prostate cancer.

— Potential Resistance —

Extensive clinical data have demonstrated that AR amplification may confer resistance to androgen deprivation therapy[53,69-71] or androgen receptor signaling inhibitors (ARSIs) such as abiraterone and enzalutamide[72-75], although a few studies have suggested that AR amplification confers resistance to enzalutamide but not to abiraterone[76], or its presence does not preclude response to ARSIs[77].

— Nontargeted Approaches —

AR signaling may promote radioresistance in prostate cancer by transcriptionally upregulating DNA repair genes[78]. There is preclinical evidence that development of resistance to anti-AR therapies, such as abiraterone and enzalutamide, may engender cross-resistance to the taxanes docetaxel and cabazitaxel[79]; however, certain AR-Vs may remain sensitive to taxanes[80-81]. Clinical data from a small Phase 2 study[82] and a small retrospective analysis[83] suggest that AR amplification may be associated with inferior outcomes for patients with CRPC treated with PSMA-targeted radionuclide-based therapies such as lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617). In the context of chemotherapy, AR amplification was associated with favorable outcomes in time to next treatment or OS for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with taxanes versus novel hormonal therapies such as enzalutamide or abiraterone[84-85]. In a meta-analysis study, AR gain did not affect OS and PFS for patients treated with first-line docetaxel or second- or third-line cabazitaxel but was associated with reduced response in later lines of docetaxel[86]. For patients with poor-prognosis CRPC treated with either cabazitaxel followed by androgen receptor pathway inhibitors (ARPIs) or ARPIs followed by cabazitaxel, AR amplification was significantly associated with shorter time to progression for both ARPIs and cabazitaxel, without significant difference observed between the 2 methods of treatment[87]. Although the radioligand therapy 177Lu-PSMA-617 is recommended for patients with PSMA-positive mCRPC previously treated with novel hormonal therapy and a taxane-based chemotherapy (NCCN Prostate Cancer Guidelines, v.4.2022), the presence of AR amplification has been associated with poor outcomes for patients with PSMA-positive mCRPC treated with 177Lu-PSMA-617 in a Phase 2 trial[82].

FREQUENCY & PROGNOSIS

Aberrant activation of AR through mutation and amplification of AR has been shown to be fundamental to prostate cancer progression; AR amplification is rare in hormone-naive prostate cancer[69-70,88-90], but has been reported for 13-49% of patients with castration-resistant prostate cancer (CRPC) following progression on androgen-deprivation therapy or AR pathway inhibitors, such as abiraterone or enzalutamide[69-71,89,91-100]. Some studies have shown that AR amplification was significantly more common for patients who progressed on enzalutamide than for those who progressed on abiraterone or other agents[97,101]. AR copy number gain is associated with increased Gleason score, increased baseline prostate-specific antigen (PSA), more advanced clinical stage, and disease progression[71,74,88], and is significantly associated with worse OS in castration-resistant prostate cancer (CRPC)[74,85,87,102-103]. For patients with CRPC treated with enzalutamide or abiraterone, AR copy number gain or amplification has been associated with worse outcomes[97,104-108]; however, AR amplification does not always correlate with poor outcomes on these treatments[77,98].

FINDING SUMMARY

AR encodes the androgen receptor, a nuclear receptor that binds to testosterone and dihydroxytestosterone. AR is frequently amplified and overexpressed in castration-resistant prostate cancer (CRPC), also called hormone-refractory prostate cancer[109].

GENE
BCOR

ALTERATION
S301fs*11

TRANSCRIPT ID
NM_017745.5

CODING SEQUENCE EFFECT
901_902insT

VARIANT CHROMOSOMAL POSITION
chrX:39933697

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no targeted therapies available to address BCOR alterations.

FREQUENCY & PROGNOSIS

BCOR alteration (mutation or homozygous deletion) has been reported in 5.4% of rhabdomyosarcoma cases, with BCOR alterations occurring more frequently in PAX fusion-negative tumors (7%) than PAX fusion-positive (1.9%) tumors[110]; BCOR mutation has also been reported in 3.2% (3/92) of medulloblastoma cases[111]. In the context of hematologic disease, BCOR mutation has also been reported in 4% of aplastic anemia cases[112], 4.2% of myelodysplastic syndrome (MDS) cases[113], 7.2% of chronic myelomonocytic leukemia cases[113], and 3.8% of normal karyotype acute myeloid leukemia (AML) cases[114]. Published data investigating the prognostic implications of BCOR mutations or inactivating alterations in solid tumors are generally limited (PubMed, Jun 2022).

FINDING SUMMARY

BCOR encodes a transcriptional corepressor that interacts with BCL6 but not with related POZ domain-containing proteins[115]. BCOR activity is required for normal development; de novo germline mutations in BCOR have been linked to syndromic microphthalmia-2 and oculofaciocardiodental syndrome[116]. BCOR inactivation has been reported in various malignancies, whereas BCOR fusions and internal tandem duplications (ITDs) are characteristic of specific tumor types[117-126].

GENE
DNMT3A

ALTERATION
splice site 2174-1G>C

TRANSCRIPT ID
NM_022552.3

CODING SEQUENCE EFFECT
2174-1G>C

VARIANT CHROMOSOMAL POSITION
chr2:25463320

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no targeted therapies available to address genomic alterations in DNMT3A in solid tumors.

FREQUENCY & PROGNOSIS

DNMT3A alterations have been reported at relatively low frequencies in solid tumors and are more prevalent in hematological malignancies (cBioPortal, Feb 2022)[127-128]. Published data investigating the prognostic implications of DNMT3A alterations in solid tumors are limited (PubMed, Feb 2022).

FINDING SUMMARY

The DNMT3A gene encodes the protein DNA methyltransferase 3A, an enzyme that is involved in the methylation of newly synthesized DNA, a function critical for gene regulation[129-130]. The role of DNMT3A in cancer is uncertain, as some reports describe increased expression and contribution to tumor growth, whereas others propose a role for DNMT3A as a tumor suppressor[131-136]. Alterations such as seen here may disrupt DNMT3A function or expression[137-140].

POTENTIAL CLONAL HEMATOPOIESIS IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion[141-146]. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy[141-142]. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease[147]. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH[145,148-149]. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

GENE
TP53

ALTERATION
T125R

TRANSCRIPT ID
NM_000546.4

CODING SEQUENCE EFFECT
374C>G

VARIANT CHROMOSOMAL POSITION
chr17:7579313

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib[150-153] or p53 gene therapy such as SGT53[154-158]. In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype[159]. A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum-refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer[160]. A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum-refractory TP53-mutated ovarian cancer[161]. The combination of adavosertib with paclitaxel and carboplatin for patients with TP53-mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone[162]. In the Phase 2 VIKTORY trial, patients with TP53-mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel[163]. A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations[164]. The Phase 2 FOCUS4-C trial for patients with TP53- and RAS-mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring[165]. In a Phase 1b clinical trial of SGT-53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage[158]. Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53-positive high-grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR[166]. A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29)[167].

FREQUENCY & PROGNOSIS

TP53 mutations have been reported in 18-40% of prostate cancers[168-169]. Overexpression of p53, which is indicative of TP53 dysregulation, has been reported to be significantly more common in late-stage and hormone-refractory prostate cancers and has been found to be associated with prostate-specific antigen (PSA) recurrence in low- and intermediate-grade prostate cancer[170]. TP53 loss has been found to be associated with prostate cancer-specific mortality in univariate analysis[171].

FINDING SUMMARY

Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers[172]. Alterations such as seen here may disrupt TP53 function or expression[173-177].

POTENTIAL GERMLINE IMPLICATIONS

One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li-Fraumeni syndrome (ClinVar, Sep 2022)[178]. Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li-Fraumeni syndrome and the early onset of many cancers[179-181], including sarcomas[182-183]. Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000[184] to 1:20,000[183]. For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30[185]. In the appropriate clinical context, germline testing of TP53 is recommended.

POTENTIAL CLONAL HEMATOPOIESIS IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion[141-146]. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy[141-142]. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease[147]. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH[145,148-149]. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

IMPORTANT Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. There may also be compassionate use or early access programs available, which are not listed in this report. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials are not ranked in order of potential or predicted efficacy for this patient or in order of level of evidence for this patient's tumor type. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. However, clinicaltrials.gov does not list all clinical trials that might be available.

GENE
AR

ALTERATION
amplification

RATIONALE
AR activation may predict sensitivity to selective p300/CBP bromodomain inhibitors.

NCT03568656

PHASE 1/2

Study to Evaluate CCS1477 in Advanced Tumours

TARGETS
EP300, CREBBP

LOCATIONS: Stockholm (Sweden), Amsterdam (Netherlands), Newcastle (United Kingdom), Edinburgh (United Kingdom), Glasgow (United Kingdom), Cambridge (United Kingdom), Manchester (United Kingdom), Leicester (United Kingdom), Sutton (United Kingdom), Birmingham (United Kingdom)

NCT04575766

PHASE 1

A Study of FT-7051 in Men With MCRPC

TARGETS
CREBBP, EP300

LOCATIONS: Colorado, Arizona, Illinois, Missouri, New York, Maryland, North Carolina, South Carolina

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

CBFB
E163G

CD274 (PD-L1)
L142S

CUL3
V723G

DAXX
R270H

KIT
S713F

PALB2
V221I

SYK
amplification

Electronically signed by J. Keith Killian, M.D. | 21 December 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *) ; 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

ABL1 **Exons 4-9**	*ACVR1B*	***AKT1*** **Exon 3**	*AKT2*	*AKT3*	***ALK*** **Exons 20-29, Introns 18, 19**	*ALOX12B*	*AMER1* (FAM123B or WTX)	***APC***
AR	***ARAF*** **Exons 4, 5, 7, 11, 13, 15, 16**	*ARFRP1*	*ARID1A*	*ASXL1*	***ATM***	***ATR***	*ATRX*	*AURKA*
AURKB	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*	*BCL6*
BCOR	*BCORL1*	*BCR** Introns 8, 13, 14	***BRAF*** **Exons 11-18,** Introns 7-10	***BRCA1*** Introns 2, 7, 8, 12, 16, 19, 20	***BRCA2*** Intron 2	*BRD4*	*BRIP1*	*BTG1*
BTG2	***BTK*** **Exons 2, 15**	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*	***CCND1***	*CCND2*
CCND3	*CCNE1*	*CD22*	*CD70*	*CD74** Introns 6-8	*CD79A*	*CD79B*	***CD274*** **(PD-L1)**	*CDC73*
CDH1	***CDK12***	***CDK4***	***CDK6***	*CDK8*	*CDKN1A*	*CDKN1B*	***CDKN2A***	*CDKN2B*
CDKN2C	*CEBPA*	*CHEK1*	***CHEK2***	*CIC*	*CREBBP*	***CRKL***	*CSF1R*	*CSF3R*
CTCF	*CTNNA1*	***CTNNB1*** **Exon 3**	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*	*DAXX*	*DDR1*
DDR2 **Exons 5, 17, 18**	*DIS3*	*DNMT3A*	*DOT1L*	*EED*	***EGFR*** **Introns 7,** 15, **24-27**	*EMSY* (C11orf30)	*EP300*	*EPHA3*
EPHB1	*EPHB4*	***ERBB2***	***ERBB3*** **Exons 3, 6, 7, 8, 10, 12, 20, 21, 23, 24, 25**	*ERBB4*	*ERCC4*	*ERG*	***ERRFI1***	***ESR1*** **Exons 4-8**
*ETV4** Intron 8	*ETV5** Introns 6, 7	***ETV6**** **Introns 5, 6**	*EWSR1** Introns 7-13	***EZH2*** **Exons 4, 16, 17, 18**	*EZR** Introns 9-11	*FANCA*	*FANCC*	*FANCG*
FANCL	*FAS*	*FBXW7*	*FGF10*	*FGF12*	*FGF14*	*FGF19*	*FGF23*	*FGF3*
FGF4	*FGF6*	***FGFR1*** Introns 1, 5, **Intron 17**	***FGFR2*** Intron 1, **Intron 17**	***FGFR3*** **Exons 7, 9 (alternative designation exon 10), 14, 18, Intron 17**	*FGFR4*	*FH*	*FLCN*	*FLT1*
FLT3 **Exons 14, 15, 20**	***FOXL2***	*FUBP1*	*GABRA6*	*GATA3*	*GATA4*	*GATA6*	*GID4* (C17orf39)	***GNA11*** **Exons 4, 5**
GNA13	***GNAQ*** **Exons 4, 5**	***GNAS*** **Exons 1, 8**	*GRM3*	*GSK3B*	*H3-3A* (H3F3A)	*HDAC1*	*HGF*	*HNF1A*
HRAS **Exons 2, 3**	*HSD3B1*	*ID3*	***IDH1*** **Exon 4**	***IDH2*** **Exon 4**	*IGF1R*	*IKBKE*	*IKZF1*	*INPP4B*
IRF2	*IRF4*	*IRS2*	*JAK1*	***JAK2*** **Exon 14**	***JAK3*** **Exons 5, 11, 12, 13, 15, 16**	*JUN*	*KDM5A*	*KDM5C*
KDM6A	*KDR*	*KEAP1*	*KEL*	***KIT*** **Exons 8, 9, 11, 12, 13, 17,** Intron 16	*KLHL6*	*KMT2A* (MLL) Introns 6, 8-11, Intron 7	*KMT2D* (MLL2)	***KRAS***

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *) ; 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

LTK	*LYN*	*MAF*	***MAP2K1*** **(MEK1) Exons 2, 3**	***MAP2K2*** **(MEK2) Exons 2-4, 6, 7**	*MAP2K4*	*MAP3K1*	*MAP3K13*	*MAPK1*
MCL1	***MDM2***	*MDM4*	*MED12*	*MEF2B*	*MEN1*	*MERTK*	***MET***	*MITF*
MKNK1	*MLH1*	***MPL*** **Exon 10**	*MRE11* (MRE11A)	*MSH2* Intron 5	*MSH3*	*MSH6*	*MST1R*	*MTAP*
MTOR **Exons 19, 30, 39, 40, 43-45, 47, 48, 53, 56**	*MUTYH*	*MYB** Intron 14	***MYC*** **Intron 1**	*MYCL* (MYCL1)	***MYCN***	***MYD88*** **Exon 4**	*NBN*	***NF1***
NF2	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2* Intron 26	*NOTCH3*	***NPM1*** **Exons 4-6, 8, 10**	***NRAS*** **Exons 2, 3**
NSD2 (WHSC1 or MMSET)	*NSD3* (WHSC1L1)	*NT5C2*	***NTRK1*** **Exons 14, 15, Introns 8-11**	*NTRK2* Intron 12	***NTRK3*** **Exons 16, 17**	*NUTM1** Intron 1	*P2RY8*	***PALB2***
PARP1	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1* (PD-1)	***PDCD1LG2*** **(PD-L2)**	***PDGFRA*** **Exons 12, 18, Introns 7, 9, 11**	***PDGFRB*** **Exons 12-21, 23**
PDK1	*PIK3C2B*	*PIK3C2G*	***PIK3CA*** **Exons 2, 3, 5-8, 10, 14, 19, 21 (Coding Exons 1, 2, 4-7, 9, 13, 18, 20)**	*PIK3CB*	*PIK3R1*	*PIM1*	*PMS2*	*POLD1*
POLE	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*	*PRKN* (PARK2)	*PTCH1*
PTEN	***PTPN11***	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*	*RAD51B*	*RAD51C*
RAD51D	*RAD52*	*RAD54L*	***RAF1*** **Exons 3, 4, 6, 7, 10, 14, 15, 17,** Introns 4-8	*RARA* Intron 2	***RB1***	*RBM10*	*REL*	***RET*** Introns 7, 8, **Exons 11, 13-16, Introns 9-11**
RICTOR	*RNF43*	***ROS1*** **Exons 31, 36-38, 40, Introns 31-35**	*RPTOR*	*RSPO2** Intron 1	*SDC4** Intron 2	*SDHA*	*SDHB*	*SDHC*
SDHD	*SETD2*	*SF3B1*	*SGK1*	*SLC34A2** Intron 4	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*
SMO	*SNCAIP*	*SOCS1*	*SOX2*	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*
STAT3	***STK11***	*SUFU*	*SYK*	*TBX3*	*TEK*	*TENT5C* (FAM46C)	*TERC** ncRNA	***TERT**** **Promoter**
TET2	*TGFBR2*	*TIPARP*	*TMPRSS2** Introns 1-3	*TNFAIP3*	*TNFRSF14*	***TP53***	*TSC1*	*TSC2*
TYRO3	*U2AF1*	***VEGFA***	*VHL*	*WT1*	*XPO1*	*XRCC2*	*ZNF217*	*ZNF703*

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Microsatellite (MS) status
Blood Tumor Mutational Burden (bTMB)
Tumor Fraction

FoundationOne Liquid CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. The CE-IVD regulatory status of FoundationOne Liquid CDx is applicable in countries that accept and/or recognize the CE mark.

CE IVD

ABOUT FOUNDATIONONE LIQUID CDx

FoundationOne Liquid CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne Liquid CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details.

INTENDED USE

FoundationOne Liquid CDx is a next generation sequencing based *in vitro* diagnostic device that analyzes 324 genes. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The test also detects the genomic signatures blood tumor mutational burden (bTMB), microsatellite instability (MSI), and tumor fraction. FoundationOne Liquid CDx utilizes circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with targeted therapies in accordance with the approved therapeutic product labeling. Additionally, FoundationOne Liquid CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with malignant neoplasms.

TEST PRINCIPLES

The FoundationOne Liquid CDx assay is performed exclusively as a laboratory service using circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood from patients with solid malignant neoplasms. The assay employs a single DNA extraction method to obtain cfDNA from plasma from whole blood. Extracted cfDNA undergoes whole-genome shotgun library construction and hybridization-based capture of 324 cancer-related genes including coding exons and select introns of 309 genes, as well as only select intronic regions or non-coding regions of 15 genes. Hybrid-capture selected libraries are sequenced with deep coverage using the NovaSeq® 6000 platform. Sequence data are processed using a customized analysis pipeline designed to accurately detect genomic alterations, including base substitutions, indels, select copy number variants, and select genomic rearrangements. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The assay also reports tumor fraction, and genomic signatures including MSI and bTMB. A subset of targeted regions in 75 genes is baited for increased sensitivity.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. *Note:* A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

QUALIFIED ALTERATION CALLS (EQUIVOCAL)

All equivocal calls, regardless of alteration type, imply that there is adequate evidence to call the alteration with confidence. However, the repeatability of equivocal calls may be lower than non-equivocal calls.

RANKING OF THERAPIES AND CLINICAL TRIALS

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

LIMITATIONS

1. For *in vitro* diagnostic use.
2. For prescription use only. This test must be ordered by a qualified medical professional in accordance with clinical laboratory regulations.
3. A negative result does not rule out the presence of a mutation below the limits of detection of the assay. Patients for whom no companion diagnostic alterations are detected should be considered for confirmation with an appropriately validated tumor tissue test, if available.
4. The FoundationOne Liquid CDx assay does not detect heterozygous deletions.
5. The test is not intended to provide information on cancer predisposition.
6. Performance has not been validated for cfDNA input below the specified minimum input.
7. Tissue TMB and blood TMB (bTMB) are estimated from the number of synonymous and nonsynonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of ≥5%, and bTMB is calculated based on variants with an allele frequency of ≥0.5%.
8. Tumor fraction is the percentage of circulating tumor DNA (ctDNA) present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate is computationally derived from the observed level of aneuploidy in the sample. Tumor fraction is considered elevated when ctDNA levels are high enough that aneuploidy can be detected and is significantly distinct from that typically found in non-tumor samples.
9. Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the tumor genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor. The MSI algorithm is based on genome wide analysis of 1765 microsatellite loci and not based on the 5 or 7 MSI loci described in current clinical practice guidelines for solid tissue testing.
10. Genomic findings from circulating cell-free DNA (cfDNA) may originate from circulating tumor DNA fragments, germline alterations, or non-tumor somatic alterations, such as clonal hematopoiesis of indeterminate potential (CHIP). Genes with alterations that may be derived from CHIP include, but are not limited to: *ASXL1*, *ATM*, *CBL*, *CHEK2*, *DNMT3A*, *JAK2*,

KMT2D (*MLL2*), *MPL*, *MYD88*, *SF3B1*, *TET2*, *TP53*, and *U2AF1*.

11. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. If a reported alteration is suspected to be germline, confirmatory testing should be considered in the appropriate clinical context.
12. The test is not intended to replace germline testing or to provide information about cancer predisposition.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >30%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, ATM, CBL, CHEK2, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2,* and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne Liquid CDx.

TREATMENT DECISIONS ARE THE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this test or the information contained in this report.

Certain sample of variant characteristics may result in reduced sensitivity. These include: low sample quality, deletions and insertions >40bp, or repetitive/high homology sequences. FoundationOne Liquid CDx is performed using cell-free DNA, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
Muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

REFERENCE SEQUENCE INFORMATION

Sequence data is mapped to the human genome, Genome Reference Consortium Human Build 37 (GRCh37), also known as hg19.

MR Suite Version (RG) 7.4.0

Electronically signed by J. Keith Killian, M.D. | 21 December 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

1. Gandara DR, et al. Nat. Med. (2018) pmid: 30082870
2. Wang Z, et al. JAMA Oncol (2019) pmid: 30816954
3. Sturgill EG, et al. Oncologist (2022) pmid: 35274716
4. Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950
5. Schenker et al., 2022; AACR Abstract CT022
6. Saori et al., 2021; ESMO Abstract 80P
7. Chen EX, et al. JAMA Oncol (2020) pmid: 32379280
8. Rizvi NA, et al. JAMA Oncol (2020) pmid: 32271377
9. Si H, et al. Clin Cancer Res (2021) pmid: 33355200
10. Leighl NB, et al. J Thorac Oncol (2022) pmid: 34800700
11. Li et al., 2020; ASCO Abstract 6511
12. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
13. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
14. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
15. Rizvi NA, et al. Science (2015) pmid: 25765070
16. Johnson BE, et al. Science (2014) pmid: 24336570
17. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
18. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
19. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
20. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
21. Nature (2012) pmid: 22810696
22. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
23. Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679
24. Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454
25. Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573
26. Choudhury AD, et al. JCI Insight (2018) pmid: 30385733
27. Goodall J, et al. Cancer Discov (2017) pmid: 28450425
28. Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207
29. Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385
30. Lapin M, et al. J Transl Med (2018) pmid: 30400802
31. Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550
32. Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117
33. Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095
34. Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681
35. Fan G, et al. PLoS ONE (2017) pmid: 28187169
36. Vu et al., 2020; DOI: 10.1200/PO.19.00204
37. Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320
38. Zhang EW, et al. Cancer (2020) pmid: 32757294
39. Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418
40. Patel JC, et al. Prostate Cancer (2013) pmid: 23819055
41. Chowdhury S, et al. Practitioner (2013) pmid: 23724747
42. Ahmed SR, et al. Lancet (1983) pmid: 6135909
43. Smith MR, et al. N. Engl. J. Med. (2018) pmid: 29420164
44. Fizazi K, et al. N. Engl. J. Med. (2019) pmid: 30763142
45. Fizazi K, et al. Lancet Oncol. (2014) pmid: 24974051
46. Soifer HS, et al. J. Biol. Chem. (2012) pmid: 22174412
47. Nat Rev Clin Oncol (2011) pmid: 21808270
48. Hird AE, et al. Clin Genitourin Cancer (2020) pmid: 32278840
49. van der Steen T, et al. Int J Mol Sci (2013) pmid: 23863692
50. Lee E, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 24019458
51. Gowda PS, et al. Mol. Cancer Res. (2013) pmid: 23989930
52. Liu LL, et al. Oncogene (2014) pmid: 23851510
53. Wadosky KM, et al. Oncotarget (2016) pmid: 27487144
54. Loddick SA, et al. Mol. Cancer Ther. (2013) pmid: 23861347
55. Rathkopf DE, et al. J. Clin. Oncol. (2013) pmid: 24002508
56. Smith MR, et al. Eur. Urol. (2016) pmid: 27160947
57. Rathkopf DE, et al. Clin. Cancer Res. (2017) pmid: 28213364
58. Soh SF, et al. J Pharm Biomed Anal (2014) pmid: 24042123
59. Bianchini D, et al. Br. J. Cancer (2013) pmid: 24169353
60. Li H, et al. Mol. Cancer Ther. (2013) pmid: 23939374
61. McKay RR, et al. Clin. Cancer Res. (2017) pmid: 27683182
62. Asangani IA, et al. Nature (2014) pmid: 24759320
63. Asangani IA, et al. Mol. Cancer Res. (2016) pmid: 26792867
64. Faivre EJ, et al. Mol. Cancer Res. (2017) pmid: 27707886
65. Piha-Paul SA, et al. Clin. Cancer Res. (2019) pmid: 31420359
66. Chan SC, et al. Nucleic Acids Res. (2015) pmid: 25908785
67. Welti J, et al. Cancer Discov (2021) pmid: 33431496
68. Armstrong et al., 2021; AACR-NCI-EORTC Abstract P202
69. Visakorpi T, et al. Nat. Genet. (1995) pmid: 7795646
70. Koivisto P, et al. Cancer Res. (1997) pmid: 9000575
71. Waltering KK, et al. Mol Cell Endocrinol (2012) pmid: 22245783
72. Du M, et al. Prostate Cancer Prostatic Dis (2020) pmid: 32203070
73. Dong B, et al. J Natl Compr Canc Netw (2021) pmid: 33990090
74. Kohli M, et al. EBioMedicine (2020) pmid: 32268276
75. McKay RR, et al. Clin Cancer Res (2021) pmid: 33849963
76. Sakamoto et al., 2019; ASCO GI 314
77. Annala M, et al. Cancer Discov (2018) pmid: 29367197
78. Bartek J, et al. Cancer Discov (2013) pmid: 24203954
79. van Soest RJ, et al. Eur. J. Cancer (2013) pmid: 24200698
80. Scher HI, et al. JAMA Oncol (2016) pmid: 27262168
81. Antonarakis ES, et al. JAMA Oncol (2015) pmid: 26181238
82. De Giorgi U, et al. Br J Cancer (2021) pmid: 34333554
83. Vlachostergios et al., 2019; AACR Abstract 4865
84. Graf RP, et al. Eur Urol (2021) pmid: 34716049
85. Conteduca V, et al. Eur Urol (2019) pmid: 30773204
86. Tolmeijer et al., 2020; DOI: 10.1200/PO.20.00084
87. Annala M, et al. Ann Oncol (2021) pmid: 33836265
88. Merson S, et al. Br J Cancer (2014) pmid: 24481405
89. Bubendorf L, et al. Cancer Res. (1999) pmid: 10029066
90. Linja MJ, et al. Cancer Res (2001) pmid: 11325816
91. Palmberg C, et al. J. Urol. (2000) pmid: 11061898
92. Haapala K, et al. Hum. Pathol. (2007) pmid: 17217995
93. Schrecengost R, et al. Semin. Oncol. (2013) pmid: 23806491
94. Schmidt LJ, et al. Curr Drug Targets (2013) pmid: 23565753
95. Grasso CS, et al. Nature (2012) pmid: 22722839
96. Taylor BS, et al. Cancer Cell (2010) pmid: 20579941
97. Azad AA, et al. Clin. Cancer Res. (2015) pmid: 25712683
98. Belic J, et al. Int J Cancer (2018) pmid: 29574703
99. Wyatt AW, et al. JAMA Oncol (2016) pmid: 27148695
100. Sonpavde G, et al. Cancer (2019) pmid: 30620391
101. Attard G, et al. Cancer Res (2009) pmid: 19339269
102. Kubota Y, et al. World J Urol (2021) pmid: 33675416
103. Kohli M, et al. Prostate Cancer Prostatic Dis (2018) pmid: 29858592
104. Annala M, et al. Clin Cancer Res (2021) pmid: 34083234
105. Del Re M, et al. Prostate Cancer Prostatic Dis (2021) pmid: 33500577
106. Conteduca V, et al. Ann Oncol (2017) pmid: 28472366
107. Romanel A, et al. Sci Transl Med (2015) pmid: 26537258
108. Salvi S, et al. Oncotarget (2016) pmid: 27191887
109. Niraula S, et al. Horm Cancer (2012) pmid: 22124843
110. Shern JF, et al. Cancer Discov (2014) pmid: 24436047
111. Pugh TJ, et al. Nature (2012) pmid: 22820256
112. Kulasekararaj AG, et al. Blood (2014) pmid: 25139356
113. Damm F, et al. Blood (2013) pmid: 24047651
114. Grossmann V, et al. Blood (2011) pmid: 22012066
115. Huynh KD, et al. Genes Dev. (2000) pmid: 10898795
116. Ng D, et al. Nat. Genet. (2004) pmid: 15004558
117. Pierron G, et al. Nat. Genet. (2012) pmid: 22387997
118. Kao YC, et al. Am. J. Surg. Pathol. (2016) pmid: 27428733
119. Specht K, et al. Am. J. Surg. Pathol. (2016) pmid: 26752546
120. Panagopoulos I, et al. Genes Chromosomes Cancer (2013) pmid: 23580382
121. Antonescu CR, et al. Genes Chromosomes Cancer (2014) pmid: 24285434
122. Astolfi A, et al. Oncotarget (2015) pmid: 26516930
123. Roy A, et al. Nat Commun (2015) pmid: 26573325
124. Kao YC, et al. Am. J. Surg. Pathol. (2016) pmid: 26945340
125. Cramer SL, et al. J Natl Compr Canc Netw (2017) pmid: 28687574
126. Appay R, et al. Am. J. Surg. Pathol. (2017) pmid: 28704208
127. Cerami E, et al. Cancer Discov (2012) pmid: 22588877
128. Gao J, et al. Sci Signal (2013) pmid: 23550210
129. Trowbridge JJ, et al. Nat. Genet. (2011) pmid: 22200773
130. Prog Mol Biol Transl Sci (2011) pmid: 21507354
131. Yang J, et al. Mol Med Rep () pmid: 21887466
132. Vallböhmer D, et al. Clin Lung Cancer (2006) pmid: 16870044
133. Daskalos A, et al. Cancer (2011) pmid: 21351083
134. Fabbri M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17890317
135. Gao Q, et al. Proc. Natl. Acad. Sci. U.S.A. (2011) pmid: 22011581
136. Kim MS, et al. APMIS (2013) pmid: 23031157
137. Chen ZX, et al. J. Cell. Biochem. (2005) pmid: 15861382
138. Guo X, et al. Nature (2015) pmid: 25383530
139. Sandoval JE, et al. J. Biol. Chem. (2019) pmid: 30705090
140. Zhang ZM, et al. Nature (2018) pmid: 29414941
141. Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837
142. Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838
143. Xie M, et al. Nat. Med. (2014) pmid: 25326804
144. Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404
145. Severson EA, et al. Blood (2018) pmid: 29678827
146. Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212
147. Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320
148. Chabon JJ, et al. Nature (2020) pmid: 32269342
149. Razavi P, et al. Nat. Med. (2019) pmid: 31768066
150. Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315
151. Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033
152. Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid:

21389100
153. Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633
154. Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850
155. Xu L, et al. Mol. Med. (2001) pmid: 11713371
156. Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564
157. Kim SS, et al. Nanomedicine (2015) pmid: 25240597
158. Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628
159. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554
160. Moore et al., 2019; ASCO Abstract 5513
161. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224
162. Oza et al., 2015; ASCO Abstract 5506
163. Lee J, et al. Cancer Discov (2019) pmid: 31315834
164. Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125
165. Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072
166. Gourley et al., 2016; ASCO Abstract 5571
167. Park H, et al. ESMO Open (2022) pmid: 36084396
168. Kumar A, et al. Proc. Natl. Acad. Sci. U.S.A. (2011) pmid: 21949389
169. Beltran H, et al. Eur. Urol. (2013) pmid: 22981675
170. Schlomm T, et al. Mod. Pathol. (2008) pmid: 18552821
171. Liu W, et al. Cancer (2013) pmid: 23609948
172. Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675
173. Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249
174. Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609
175. Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130
176. Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496
177. Yamada H, et al. Carcinogenesis (2007) pmid: 17690113
178. Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669
179. Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290
180. Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100
181. Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776
182. Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316
183. Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208
184. Lalloo F, et al. Lancet (2003) pmid: 12672316
185. Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713